Vericel Corp Ord

Yahoo Finance • 2 months ago

Vericel Corp (VCEL) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ...

Total Revenue: $52.7 million for the second quarter. MACI Revenue: $44.1 million, a 21% increase year-over-year. Burn Care Revenue: $8.5 million, including Epicel revenue of $7.8 million and NexoBrid revenue of $0.8 million. Gross Margin:... Full story

Yahoo Finance • 5 months ago

Vericel Corporation (NASDAQ:VCEL) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Last week, you might have seen that Vericel Corporation (NASDAQ:VCEL) released its quarterly result to the market. The early response was not positive, with shares down 9.0% to US$47.62 in the past week. Revenues came in at US$53m, in line... Full story

Yahoo Finance • 10 months ago

Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance

Vericel Corporation Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40% Fourth Quarter Total Revenue Growth of 23% to $65.0 Million, with Adjusted EBITDA Growth of 50% Fourth Quarter Gross Ma... Full story

Yahoo Finance • last year

Insider Sell: COO Michael Halpin Sells 17,447 Shares of Vericel Corp (VCEL)

Vericel Corp (NASDAQ:VCEL), a leader in the field of regenerative medicine, has recently witnessed a significant insider transaction. The company's Chief Operating Officer, Michael Halpin, sold 17,447 shares on November 30, 2023. This move... Full story

Yahoo Finance • last year

Vericel Corporation (NASDAQ:VCEL) Q3 2023 Earnings Call Transcript

Vericel Corporation (NASDAQ:VCEL) Q3 2023 Earnings Call Transcript November 8, 2023 Vericel Corporation beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.13. Operator: Ladies and gentlemen, thank you for standing... Full story

Yahoo Finance • last year

Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance

Record Third Quarter Revenue of $45.6 Million, Representing 18% Growth versus Prior Year MACI Revenue Growth of 21% to $37.6 Million Full-Year 2023 Revenue Guidance Raised to $192.5-197.5 Million Conference Call Today at 8:30am Eastern... Full story

Yahoo Finance • last year

Vericel to Present at the Stephens Annual Investment Conference

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Ma... Full story

Yahoo Finance • last year

Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023

CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2023 financ... Full story

Yahoo Finance • last year

Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid

Data published in the Journal of Burn Care & Research show treatment with NexoBrid resulted in early complete eschar removal in more than 90% of treated patients, and reduced surgery when compared to Gel Vehicle and standard of care Resul... Full story

Yahoo Finance • last year

Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults

Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns NexoBrid launch significantly expands the total addr... Full story

Yahoo Finance • last year

Vericel to Present at the Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will part... Full story

Yahoo Finance • 2 years ago

Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance

Record First Quarter Total Revenue of $41 Million MACI Revenue Increased 32% to $34.2 Million Full-Year 2023 Revenue Guidance Raised to $184-$192 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 10, 2023 (GL... Full story

Yahoo Finance • 2 years ago

Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor

CHICAGO, May 2, 2023 /PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments of Paul K. Wotton, Ph.D., to the board of directors and Ch... Full story

Yahoo Finance • 2 years ago

Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2023 finan... Full story

Yahoo Finance • 2 years ago

Little Excitement Around Vericel Corporation's (NASDAQ:VCEL) Revenues

Vericel Corporation's (NASDAQ:VCEL) price-to-sales (or "P/S") ratio of 8.6x might make it look like a buy right now compared to the Biotechs industry in the United States, where around half of the companies have P/S ratios above 11.5x and... Full story

Yahoo Finance • 2 years ago

Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance

Record Fourth Quarter Total Revenue of $52.7 Million and 31% Net Income Growth Full-Year 2022 Total Revenue of $164.4 Million, with MACI Revenue of $132 Million Full-Year 2023 Total Revenue Guidance of $180 to $188 Million, with MACI Rev... Full story

Yahoo Finance • 2 years ago

Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023

CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter 2022 finan... Full story

Yahoo Finance • 2 years ago

Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program

Full-Year Total Revenue Expected to be Approximately $164 to $165 Million MACI Full-Year Revenue Expected to be at the High End of Guidance Range, with Fourth Quarter Revenue Growth of Approximately 24% MACI Arthroscopic Commercial Launc... Full story

Yahoo Finance • 2 years ago

Vericel scores FDA approval for $142M burn treatment

Three and a half years after licensing it from an Israeli pharma in a $142 million deal, Vericel Corporation has won FDA approval for NexoBrid, a gel designed to treat serious burns. Continue reading... Full story

Yahoo Finance • 2 years ago

MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Triggers $7.5 million milestone payment from Vericel Corporation; NexoBrid is anticipated to be commercial... Full story